Compare Bristol-Myers Squibb Co (BMY) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Freshworks Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.46 (market cap $116.30B), while Freshworks Inc trades at $10.65 (market cap $2.89B). The key difference: Bristol-Myers Squibb Co is far larger — about 40.2× Freshworks Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| BMY | FRSH | |
|---|---|---|
Market Cap | $116.30B | $2.89B |
Sector | Health | Technology |
52-Week High | $62.37 | $14.77 |
52-Week Low | $42.60 | $6.88 |
Enterprise Value | $152.24B | $2.15B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Freshworks (FRSH) trades at $10.83, up 4.54% today, with a bullish technical signal from moving averages. The company shows strong fundamental improvement, with revenue growing from $498M in 2022 to $839M in 2025 and achieving profitability with a net income margin of 20.69%. Recent news highlights AI product launches and a strategic pivot to employee experience, with Q2 2026 earnings due August 4, 2026.
The outlook is positive given consistent revenue growth, high gross margins, and analyst consensus pointing to a 26% upside. Risks include execution of the new strategic focus and competitive pressures in the SaaS sector. The stock presents a value opportunity with a P/E of 17.63, below software industry averages, supported by improving cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
